Letter

Recruitment into studies assessing optimum duration of treatment must continue

BMJ 1996; 312 doi: 10.1136/bmj.312.7037.1036b (Published 20 April 1996)
Cite this as: BMJ 1996;312:1036.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Helena Earl,
  2. Pat Baker,
  3. David Kerr,
  4. Martin Lee,
  5. Richard Gray,
  6. Michael Baum
  1. On behalf of the steering committee of the aTTom study Cochair, aTTom study Senior trial coordinator Professor of oncology CRC Trials Unit, CRC Institute for Cancer Studies, University of Birmingham, Queen Elizabeth Hospital, Birmingham B15 2TT
  2. Cochair, aTTom study City Hospital NHS Trust, Birmingham B18 7QH
  3. Senior research statistician, aTTom study Clinical Trial Service Unit, Radcliffe Infirmary, University of Oxford, Oxford OX2 6HE
  4. Professor of surgery Royal Marsden Hospital, London SW3 6JJ

    EDITOR,—R D Bulbrook's editorial prejudges the issue of the duration of tamoxifen as adjuvant treatment for breast cancer.1 Its conclusions are based on an announcement by the American National Cancer Institute that the national surgical adjuvant breast and bowel project trial B-14, which compared five with up to 10 years of tamoxifen, was to be stopped on the advice of the data monitoring committee. On the basis of unpublished data from just over 1500 randomised patients from this and a Scottish study …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular